Cargando…

Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion

OBJECTIVE: Lymphangioleiomyomatosis (LAM) is a rare, destructive disease of the lungs with a limited number of determinants of disease activity, which are a critical need for clinical trials. FGF23 has been implicated in several chronic pulmonary diseases. We aimed to determine the association betwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esposito, Anthony J, Imani, Jewel, Shrestha, Shikshya, Bagwe, Shefali, Lamattina, Anthony M, Vivero, Marina, Goldberg, Hilary J, Rosas, Ivan O, Henske, Elizabeth P, El-Chemaly, Souheil Y
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171272/ https://www.ncbi.nlm.nih.gov/pubmed/37132737 http://dx.doi.org/10.36416/1806-3756/e20220356

Ejemplares similares

Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis
por: Lamattina, Anthony M., et al.
Publicado: (2019)

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
por: Courtwright, Andrew M., et al.
Publicado: (2017)

Angiotensin II receptor type 1 blockade regulates Klotho expression to induce TSC2-deficient cell death
por: Shrestha, Shikshya, et al.
Publicado: (2022)

Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer
por: El-Chemaly, Souheil, et al.
Publicado: (2014)

Hyaluronan and LYVE-1 and allograft function in lung transplantation recipients
por: Courtwright, Andrew M., et al.
Publicado: (2019)

FK506 induces lung lymphatic endothelial cell senescence and downregulates LYVE-1 expression, with associated decreased hyaluronan uptake
por: Shrestha, Shikshya, et al.
Publicado: (2020)

Blocking hyaluronan synthesis alleviates acute lung allograft rejection
por: Imani, Jewel, et al.
Publicado: (2021)

ETV2 regulates PARP-1 binding protein to induce ER stress–mediated death in tuberin-deficient cells
por: Shrestha, Shikshya, et al.
Publicado: (2022)

The lung microbiome in end-stage Lymphangioleiomyomatosis
por: Ng, Julie, et al.
Publicado: (2021)

Glycogen synthase kinase 3-β inhibition induces lymphangiogenesis through β-catenin-dependent and mTOR-independent pathways
por: Stump, Benjamin, et al.
Publicado: (2019)

Dysregulated myosin in Hermansky-Pudlak syndrome lung fibroblasts is associated with increased cell motility
por: Imani, Jewel, et al.
Publicado: (2022)

Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival
por: Courtwright, Andrew M., et al.
Publicado: (2020)

Lung transplant in familial pulmonary fibrosis: the road ahead
por: Esposito, Anthony Joseph, et al.
Publicado: (2020)

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
por: Tang, Yan, et al.
Publicado: (2021)

Protease activity sensors enable real-time treatment response monitoring in lymphangioleiomyomatosis
por: Kirkpatrick, Jesse D., et al.
Publicado: (2022)

Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis
por: Qiu, Min, et al.
Publicado: (2022)

Management of lymphangioleiomyomatosis
por: Taveira-DaSilva, Angelo M., et al.
Publicado: (2014)

Lymphangioleiomyomatosis (LAM)
Publicado: (2017)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Phosphate and FGF-23
por: Jüppner, Harald
Publicado: (2011)

FGF23 and inflammation
por: Sharaf El Din, Usama A A, et al.
Publicado: (2017)

FGF23 and Fetuin-A Interaction in the Liver and in the Circulation
por: Mattinzoli, Deborah, et al.
Publicado: (2018)

Treatment of lymphangioleiomyomatosis and Camões
por: Rufino, Rogério
Publicado: (2015)

Methylprednisolone in the treatment of lymphangioleiomyomatosis
por: Dale, Ventour, et al.
Publicado: (2022)

Chylothorax, in the Spotlight of Lymphangioleiomyomatosis
por: Gámez-Baeza, Pablo, et al.
Publicado: (2022)

FGF-23 in bone biology
por: Wesseling-Perry, Katherine
Publicado: (2009)

FGF23, Biomarker or Target?
por: Rodelo-Haad, Cristian, et al.
Publicado: (2019)

Pleiotropic Actions of FGF23
por: Erben, Reinhold G.
Publicado: (2017)

Editorial: Advances and Updates in Diffuse Cystic Lung Diseases
por: Baldi, Bruno Guedes, et al.
Publicado: (2021)

Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants
por: Enlund-Cerullo, Maria, et al.
Publicado: (2023)

Real-Time Monitoring of Tumorigenesis, Dissemination, & Drug Response in a Preclinical Model of Lymphangioleiomyomatosis/Tuberous Sclerosis Complex
por: Liu, Fangbing, et al.
Publicado: (2012)

A case of lymphangioleiomyomatosis with diffuse large B-cell lymphoma: Usefulness of FDG-PET
por: Orimo, Mami, et al.
Publicado: (2020)

Ultra-Small Lung Cysts Impair Diffusion Without Obstructing Air Flow in Lymphangioleiomyomatosis
por: Matthew, Brianna P., et al.
Publicado: (2021)

Pulmonary lymphangioleiomyomatosis in a male.
por: Kang, H. W., et al.
Publicado: (1991)

Role of Prolactin Receptors in Lymphangioleiomyomatosis
por: Alkharusi, Amira, et al.
Publicado: (2016)

Lung Transplantation for Lymphangioleiomyomatosis in Japan
por: Ando, Katsutoshi, et al.
Publicado: (2016)

Lymphangioleiomyomatosis Presenting with Perirenal Hemorrhage
por: Dekeyzer, S., et al.
Publicado: (2015)

Recent advances in the management of lymphangioleiomyomatosis
por: Xu, Kai-Feng, et al.
Publicado: (2018)

Lymphangioleiomyomatosis Presenting as Recurrent Pneumothorax
por: Odak, Mihir, et al.
Publicado: (2020)

Lymphangioleiomyomatosis: a clinical review
por: O'Mahony, Anne M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9v69j0u5pqi7ccqk4k94t4t9u9